drug
omidenepag isopropyl
Marketedupdated 3mo agoby Ocuvex Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 22, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Jul 16, 2039method-of-use (U-3454)US 11666563
- Dec 27, 2038method-of-use (U-3454)US 12290511
- Jun 10, 2035compositionUS 10774072
- Jan 8, 2035formulationUS 10179127
- Jan 8, 2035formulationUS 10702511
- Jan 8, 2035formulationUS 10765750
- Jan 8, 2035formulationUS 11197849
- Jan 8, 2035formulationUS 11793798
- Jan 8, 2035formulationUS 12295946
- Jan 8, 2035formulationUS 9415038
- Jan 8, 2035formulationUS RE48183
- Oct 13, 2029compositionUS 86480973.2y
- Oct 13, 2029formulationUS 86859863.2y
FDA exclusivities (1)
- Sep 22, 2027NCENew Chemical Entity (5y)1.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that